worth buying post Earnings results? NASDAQ:ENLV, NASDAQ:CLSD, NASDAQ:KMPH, NASDAQ:LVOX

ENLIVEX THERAPEUTICS (NASDAQ:ENLV) EARNINGS INFORMATION (NASDAQ:ENLV)

Enlivex Therapeutics last released its earnings data on June 1st, 2021. The reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.02. Enlivex Therapeutics has generated ($0.90) earnings per share over the last year (($1.01) diluted earnings per share). Earnings for Enlivex Therapeutics are expected to decrease in the coming year, from ($1.01) to ($1.60) per share. Enlivex Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, October 29th, 2021 based off prior year’s report dates.

IS ENLIVEX THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:ENLV)

1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Enlivex Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Enlivex Therapeutics stock.
Enlivex Therapeutics

CLEARSIDE BIOMEDICAL (NASDAQ:CLSD) EARNINGS INFORMATION (NASDAQ:CLSD)

Clearside Biomedical last posted its earnings data on August 9th, 2021. The reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Clearside Biomedical has generated ($0.39) earnings per share over the last year (($0.45) diluted earnings per share). Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.26) to ($0.41) per share. Clearside Biomedical has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

IS CLEARSIDE BIOMEDICAL A BUY RIGHT NOW? (NASDAQ:CLSD)

5 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Clearside Biomedical in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Clearside Biomedical stock.
Clearside Biomedical

KEMPHARM (NASDAQ:KMPH) EARNINGS INFORMATION (NASDAQ:KMPH)

KemPharm last posted its earnings data on August 12th, 2021. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.63. KemPharm has generated ($3.00) earnings per share over the last year. Earnings for KemPharm are expected to decrease by -76.19% in the coming year, from $0.63 to $0.15 per share. KemPharm has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

IS KEMPHARM A BUY RIGHT NOW? (NASDAQ:KMPH)

2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for KemPharm in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” KemPharm stock.
KemPharm

LIVEVOX (NASDAQ:LVOX) EARNINGS INFORMATION (NASDAQ:LVOX)

LiveVox last announced its earnings data on August 12th, 2021. The reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $1.04. LiveVox has generated $0.00 earnings per share over the last year. Earnings for LiveVox are expected to grow in the coming year, from ($0.11) to ($0.10) per share. LiveVox has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

IS LIVEVOX A BUY RIGHT NOW? (NASDAQ:LVOX)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for LiveVox in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” LiveVox stock.
LiveVox